Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") has announced a strategic partnership with the AI-driven company InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "InveniAI"). This collaboration marks a pivotal moment in leveraging artificial intelligence (AI) and machine learning (ML) to revolutionize the identification of novel therapeutic targets.

The agreement outlines that InveniAI will utilize its proprietary AlphaMeld® and ChatAlphaMeld™ platforms, which incorporate advanced AI, ML algorithms, and Generative AI tools, to unearth new therapeutic targets across a range of diseases specified by Ono. These platforms are designed to analyze vast datasets, enabling the generation of drug discovery hypotheses for optimization. Ono, in turn, will undertake validation studies to confirm these hypotheses for the therapeutic target candidates identified. Crucially, Ono will have exclusive rights to develop and commercialize any drug candidates that emerge from this joint effort on a global scale.

Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research at Ono, expressed enthusiasm for the partnership, highlighting the anticipated improvements in the efficiency of drug discovery research. Takino emphasized the potential for this collaboration to foster the creation of innovative therapeutic options that could benefit patients worldwide.

Echoing this sentiment, Krishnan Nandabalan, Ph.D., President and CEO at InveniAI, LLC, underscored the significance of the collaboration as a fusion of expertise and state-of-the-art technologies aimed at accelerating the discovery of viable product opportunities. Nandabalan pointed to InveniAI's commitment to leveraging technological innovation, such as the incorporation of large language models and generative AI, exemplified by the development of ChatAlphaMeld™. This tool represents a leap forward in utilizing advanced technology tools across the organization, with a strong focus on enhancing patient outcomes.

This partnership between Ono and InveniAI embodies a shared vision for harnessing the power of AI and ML in the quest for groundbreaking advancements in drug discovery and development, promising a future of innovative solutions for challenging diseases.